AXIM BIOTECHNOLOGI (AXIM)

2.75
0.02 0.72
OTC
Prev Close 2.77
Open 2.77
Day Low/High 2.71 / 2.81
52 Wk Low/High 2.60 / 11.30
Volume 24.29K
Exchange OTC
Shares Outstanding 56.74B
Market Cap 169.64M
Div & Yield N.A. (N.A)

Latest News

AXIM Biotech Announces Successful Completion Of Exploratory Meeting With The Dutch Medicines Evaluation Board On MedChew Rx Program For Treatment Of Pain And Spasticity In MS Patients

AXIM Biotech Announces Successful Completion Of Exploratory Meeting With The Dutch Medicines Evaluation Board On MedChew Rx Program For Treatment Of Pain And Spasticity In MS Patients

AXIM Received Guidance and Approval on Its MedChew Rx Clinical Development Program from Dutch Authorities, Achieving Another Major Milestone for the Company's European Market Expansion

AXIM Biotech Announces Successful Completion Of Pre-IND Meeting With FDA On Comparable Product To Marinol; Green Light From FDA For IND Submission

AXIM Biotech Announces Successful Completion Of Pre-IND Meeting With FDA On Comparable Product To Marinol; Green Light From FDA For IND Submission

AXIM to Proceed with IND Filing of Dronabinol-Based Chewing Gum to Help Treat Chemotherapy-Related Nausea and Vomiting in Cancer and Loss of Appetite and Cachexia in HIV/AIDS Patients

Axim Biotechnologies Announces Phase IIa Trial Results Validating Its Proprietary Cannabinoid Delivery Method For Treatment Of Irritable Bowel Syndrome (IBS)

Axim Biotechnologies Announces Phase IIa Trial Results Validating Its Proprietary Cannabinoid Delivery Method For Treatment Of Irritable Bowel Syndrome (IBS)

Participants of AXIM Biotech's Phase IIa trial experienced a decrease in their pain score and improvement in their quality of life score, highlighting the efficacy of AXIM's patented CBD chewing gum delivery method, allowing for AXIM to move forward with further trials with predetermined dosing

New U.S. Patent Allowance Granted To AXIM® Biotechnologies, Inc. For Cannabinoid Ophthalmic Solutions For Glaucoma And Conjunctivitis Treatment

New U.S. Patent Allowance Granted To AXIM® Biotechnologies, Inc. For Cannabinoid Ophthalmic Solutions For Glaucoma And Conjunctivitis Treatment

New Patent Granted to AXIM Allows Use of Cannabinoid-Based Ophthalmic Solutions to Treat Glaucoma and Conjunctival Inflammation